Full Service Clinical Trial Management

Our acute MHRA accredited Phase I environment, in- and out-patient facilities, leading technology and on-site therapeutic consultancy combine to offer a full service on any Early Phase study.

We believe that effective project management is the key to meeting study timelines. We achieve this through a dedicated study team who meet, plan and document every step of your study. Our project managers are all life science graduates who provide you with a single point of contact to keep you updated on progress through each milestone.

With our exceptional bed capacity, guaranteed recruitment panels and sophisticated technology, our team of highly experienced experts provide the following services.

Protocol Writing & CRF Design

View service

Regulatory Applications

View service

Data Management

View service

Pharmacy

View service

Laboratory

View service

Drug Free Plasma

View service

In House Volunteer Catering

View service

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

What 20 years of clinical research has taught us about our industry and the future of drug development

June 9, 2021
As Richmond Pharmacology approaches its 20th anniversary our co-founder and CEO reflects on the developments, regulatory changes, and innovations within the life science industry in an article in the PharmaTimes.
Read more

Do we still need challenge trials with COVID-19?

April 21, 2021
Nir Eyal and colleagues suggested that the initiation of COVID-19 challenge trials in response to the UK governments’ call in 2020 remained relevant and important despite the development of approved vaccines and the introduction of an aggressive, UK-wide vaccination policy.
Read more

Novel rate-controlled fentanyl patch shows promise in phase I clinical trial

April 1, 2021
Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.
Read more